Literature DB >> 16952851

Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer.

Vicente Tormo Ferrero1, Francisco José Andreu Martínez, Rafael Cardenal Macía, Almudena Pomares Arias.   

Abstract

PURPOSE: In this study we evaluated the acute toxicity of the combined treatment with chemoradiotherapy, according to the scheme of McDonald et al, in patients diagnosed with gastric cancer, after radical curative surgery.
METHODS: From July 2001 to December 2005, a total of 24 patients, with diagnosis of adenocarcinoma of the stomach or adenocarcinoma of the gastroesophageal junction, who were operated with total or subtotal gastrectomy with free resection margins, were treated at our service with a combined scheme of adjuvant chemoradiotherapy.
RESULTS: Grade 3 toxicity or higher appeared in three patients (12%) and grade 2 in five of the twenty-four patients (21%). Two patients (8%) needed to suspend treatment before the scheduled end date of treatment due to acute toxicity. No acute toxicity of cardiological, hepatic or renal nature was registered, and the most frequent toxicity was the gastrointestinal toxicity (detected in the 79% of the patients).
CONCLUSIONS: Combined treatment with chemoradiotherapy, according to the scheme of Macdonald, in diagnosed patients with gastric cancer, after radical curative surgery is a well tolerated treatment, with a low degree of acute toxicity, thus the treatment compliance is not difficult.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952851     DOI: 10.1007/s12094-006-0068-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

1.  Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.

Authors:  J Ringash; S J Khaksart; A Oza; J Couture; B Japp; M Moore; L L Siu; D Hedley; C Swallow; S Wong; B Cummings; J Kim; R Wong; J Brierley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-04       Impact factor: 4.126

2.  3D conformal radiotherapy for gastric cancer--results of a comparative planning study.

Authors:  Trevor Leong; David Willis; Daryl Lim Joon; Sara Condron; Andrew Hui; Samuel Y K Ngan
Journal:  Radiother Oncol       Date:  2005-03       Impact factor: 6.280

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

5.  Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation.

Authors:  Stephen R Smalley; Leonard Gunderson; Joel Tepper; James A Martenson; Bruce Minsky; Christopher Willett; Tyvin Rich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

Review 6.  Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer.

Authors:  Joel E Tepper; Leonard L Gunderson
Journal:  Semin Radiat Oncol       Date:  2002-04       Impact factor: 5.934

Review 7.  Gastric cancer: epidemiology, pathology and treatment.

Authors:  S R Alberts; A Cervantes; C J H van de Velde
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

8.  Postoperative chemoradiotherapy for gastric cancer.

Authors:  S H Park; D Y Kim; J S Heo; D H Lim; C K Park; K W Lee; S H Choi; T S Sohn; S Kim; J H Noh; Y I Kim; J O Park; K Kim; W S Kim; C W Jung; Y H Im; M H Lee; K Park; C H Park; W K Kang
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976

  8 in total
  5 in total

Review 1.  Management of gastric adenocarcinoma.

Authors:  P Khosravi Shahi; V M Díaz Muñoz de la Espada; P García Alfonso; S Encina García; Y Izarzugaza Perón; J L Arranz Cozar; B Hernández Marín; G Pérez Manga
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

2.  Pancreatic enzyme supplementation after gastrectomy for gastric cancer: a randomized controlled trial.

Authors:  Marco Catarci; Manuele Berlanda; Giovanni Battista Grassi; Francesco Masedu; Stefano Guadagni
Journal:  Gastric Cancer       Date:  2017-08-14       Impact factor: 7.370

Review 3.  Progress of preoperative and postoperative radiotherapy in gastric cancer.

Authors:  Nan Zhang; Qian Fei; Jiajia Gu; Li Yin; Xia He
Journal:  World J Surg Oncol       Date:  2018-09-13       Impact factor: 2.754

4.  Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience.

Authors:  Casey J Allen; Alisa N Blumenthaler; Grace L Smith; Prajnan Das; Bruce D Minsky; Mariela Blum; Jaffer Ajani; Paul F Mansfield; Naruhiko Ikoma; Brian D Badgwell
Journal:  Ann Surg Oncol       Date:  2020-07-21       Impact factor: 5.344

5.  Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.

Authors:  Casey J Allen; David T Pointer; Alisa N Blumenthaler; Rutika J Mehta; Sarah E Hoffe; Bruce D Minsky; Grace L Smith; Mariela Blum; Paul F Mansfield; Naruhiko Ikoma; Prajnan Das; Jaffer Ajani; Sean P Dineen; Jason B Fleming; Brian D Badgwell; Jose M Pimiento
Journal:  Ann Surg       Date:  2021-10-01       Impact factor: 13.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.